Financials

	2022	2023
Net sales	54.13M 47.16M 43.48M 40.89M 76.5M 5.1B 77.04M 517M 201M 2.51B 203M 199M 8.71B	80.75M 70.36M 64.86M 61.01M 114M 7.61B 115M 772M 300M 3.75B 303M 297M 13B
Net income	-18.11M -15.78M -14.54M -13.68M -25.59M -1.71B -25.77M -173M -67.2M -841M -67.96M -66.51M -2.91B	-20.13M -17.54M -16.17M -15.21M -28.45M -1.9B -28.65M -192M -74.71M -935M -75.57M -73.95M -3.24B
Net Debt	42.09M 36.67M 33.81M 31.8M 59.49M 3.97B 59.91M 402M 156M 1.95B 158M 155M 6.78B	55.34M 48.22M 44.45M 41.81M 78.22M 5.22B 78.77M 529M 205M 2.57B 208M 203M 8.91B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 16:00:00 2024-09-13 EDT			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

24-09-16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
24-09-15	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 263M 242M 228M 426M 28.4B 429M 2.88B 1.12B 13.99B 1.13B 1.11B 48.5B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 311M 286M 269M 504M 33.61B 508M 3.41B 1.32B 16.56B 1.34B 1.31B 57.41B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

24-09-16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
24-09-15	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
24-09-15	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
24-09-11	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
24-09-11	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
24-09-10	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
24-09-09	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
24-08-06	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-17	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

24-06-25	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
24-06-25	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
24-06-25	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
24-06-25	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
24-03-25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

24-09-16	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
24-09-11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
24-09-11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
24-09-10	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
24-09-10	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	2024-01-01
Jason Werner COO	Chief Operating Officer	48	2023-10-01
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-15	Velan Capital Investment Management LP	Issuer sale	Company	14,408,533	26.4940%
24-09-15	Elliot Maltz	Issuer sale	Chief Financial Officer	225,000	0.4137%
24-09-15	Ross DeMont	Issuer sale	Director	50,000	0.0919%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+91.03%	287M
REGENERON PHARMACEUTICALS, INC.	-1.25%	-1.96%	+16.73%	-23.26%	61.85B
UCB	-1.27%	-8.04%	+60.62%	+195.96%	55.69B
SAMSUNG BIOLOGICS CO.,LTD.	+4.38%	+43.00%	+43.00%	+43.00%	41.88B
CSL LIMITED	+1.21%	+4.98%	-54.83%	-61.10%	36.15B
BIOGEN INC.	-1.60%	-2.30%	+54.35%	-33.52%	29.33B
MODERNA, INC.	+3.78%	+28.24%	+150.63%	-48.76%	24.52B
INCYTE CORPORATION	-1.56%	-9.63%	+42.73%	+57.81%	19.78B
INNOVENT BIOLOGICS, INC.	+1.74%	+2.42%	-1.23%	+107.49%	16.61B
SWEDISH ORPHAN BIOVITRUM AB	-0.05%	+0.41%	+56.32%	+101.93%	16.2B
Average	+0.51%	+4.59%	+36.83%	+43.06%	30.23B
Weighted average by Cap.	+0.40%	+4.16%	+37.23%	+38.02%

3 years	2.6	5.65
5 years	1.3	9.81
10 years	0	36